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ABSTRACT
The effects of the treatment of tumor cells of MCa mammary carcinoma and TLX5 lymphoma with
the ruthenium complex Na[trans-RuCI4(DMSO)lm for several transplant generations were studied on
tumor growth and metastases formation. On TLX5 lymphoma cells, treatment was performed in vitro
prior to in vivo inoculation of tumor cells in intact or immunesuppressed mice. Either considering tumor
take and growth or its capacity to invade the brain of the inoculated hosts, Na[trans-RuCl4(DMSO)lm]
did not induce any significant modification. Conversely, in mice with MCa mammary carcinoma, the in
vivo treatment of tumor cells in immunesuppressed hosts caused a progressive increase of DNA activity
and, starting from the 4th transplant generation, a significantly increased susceptibility of lung
metastasis formation to a further treatment in intact mice. These data seem to suggest that Na[trans-
RuCI,(DMSO)Im] does not induce chemical xenogenization of tumor cells nor its repeated treatment
induces resistance in tumor cells. Conversely, it appears that Na[trans-RuCl4(DMSO)lm] may select a
tumor cell population which maintains its capacity to metastasise to the lung but with enhanced
sensitivity to the antimetastatic properties of this compound.
INTRODUCTION
The effects of a new generation ruthenium(Ill) complex, Na[trans-RuCl4(DMSO)lm], are different
from those of cisplatin in that, unlike cisplatin that is equally active on primary tumor growth and lung
colonies, Na[trans-RuCl4(DMSO)lm] is markedly effective only on spontaneous metastases (1-3). The
selectivity of Na[trans-RuCl4(DMSO)lm] on lung metastases is marked also on advanced metastases
and accounts for a significant prolongation of host’s survival time, particularly in the experiments in
which drug treatment is associated with surgical removal of primary tumor. This effect is not associated
with any residual effect on primary tumor cells after treatment discontinuation whereas it tends to
reduce the metastatic ability of the same tumor (3).
Either by means of vivo-vivo bioassays or by microscopical examination it appears that the growth of
lung tumors is markedly reduced whereas the growth of the i.m. primary tumor is much less affected
and histologically not detectable. These effects account for the prolongation of the survival time and for
the cure rate observed and highlight the pharmacological properties of this compound for the control of
solid tumor metastases, an effect that was shown to be similarly exerted also on advanced tumor
metastases (4,5).
Metastases represent the greatest obstacle to cures after surgery and/or radiotherapy in that they
often show a low chemosensitivity to the available anticancer drugs (6). The lack of success derives
from the fact that tumor metastases are always treated with drugs that have been specifically
developed by studying their activity in reducing primary tumor growth rather than by examining their
efficacy on the more selective metastatic population (7). The aim of the present investigation was that
of examining the cumulative effects of repeated treatments for several transplant generations on
primary tumor growth and lung metastasis formation using the MCa mammary carcinoma of CBA
mouse. Tumor treatment will be performed in vivo either in mice immunesuppressed by DTIC or in
intact hosts. Parallelly, in vitro treatments of TLX5 lymphoma cells for up to 13 transplant generations
will be performed to ascertain the possible occurrence of chemical xenogenizing effects, similar to
those caused by triazeno derivatives and nitrosoguanidine derivatives (8-10). This study will therefore
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focus the attention on the possible intervention of antigenic modifications on tumor cells after treatment
and on the susceptibility of treated tumor cells to further treatments in terms of modification of tumor
growth and metastasis formation.
MATERIALS AND METHODS
Comlounds and treatments. Na[trans-RuCl(DMSO)lm] was prepared according to standard
procedures (9,10). The compound was dissolved in 0.9% NaCI and was administered i.p. to mice in
volumes of 0.1 ml/10 g body weight. The dose of Na[trans-RuCl(DMSO)lm] (100 mg/Kg/day), at the
treated schedule used, is well tolerated by the treated animals and does not cause appreciable
reduction of body weight gain vs untreated controls at the end of treatment.
MCa mammary carcinoma. The line of MCa mammary carcinoma of CBA mouse was obtained from
the Rudjer Boskovich Institute, Zagreb, Croatia (11), and was maintained by biweekly passages of 10s
viable tumor cells into the calf of the left hind leg of CBA inbred female mice of 20fi2 g obtained from a
locally established breeding colony. Tumor propagation for experimental purposes was similarly carded
out using female mice 6-8 weeks old. Tumor cell suspensions were prepared from pdmary tumors of
donors similarly inoculated two weeks before. In short, 2.5 g of freshly removed tumor was minced with
scissors, finely dispersed in 20 ml Dulbecco’s phosphate saline calcium and magnesium free (PBS) and
filtered through a double layer of sterile gauze; after centrifuging at 250xg per 10 min, pelletts were
resuspended in an equal volume of PBS and cell viability was checked by the trypan blue exclusion
test: only cell suspensions with at least 55-60% viable cells were used.
Primary tumor and lung .metastasis evaluation. Pdmary tumors were measured by caliper and their
weight estimated by the following formula: (n/6)ab [Equation 1], where a and b are two perpendicular
axes (a<b) and assume tumor density equal to 1. The evaluation of the number and weight of lung
metastases, spontaneously formed from the s.c. tumor implants, was performed after the killing of the
animals by cervical dislocation. The number of lung metastases on the surface of the freshly removed
lungs was counted by means of a low-power stereo microscope equipped with a calibrated grid. The
weight of the metastatic tumor per mouse was calculated by determining the volume of each metastatic
nodule by the formula of primary tumors reported above [Equation 1].
Histolo.qical analysis. Pieces of primary tumor were collected immediately after killing of the animals
and fixed in formalin. For light transmission observations, slices were stained with hematoxylin-eosin or
with CajaI-Cailego mounted in Canada Balsam, and were observed in double blind with a Leitz-
Orthoplan microscopy.
TLX5 lymphoma. The TLX5 lymphoma line, originally obtained from the Chester Beatthy Research
Institute, London, England, was maintained by weekly passages of 10 cells/mouse i.p. into CBA mice.
For the experimental purposes, the tumor was collected from the peritoneal cavity of donor mice
inoculated one week before, and washed twice with PBS.
in vitro-in vivo bioassays. Tumor cell suspensions of TI_X5 lymphoma (10s cells/ml) were kept in vitro at
37C for 60 rain under shaking in tissue culture tubes with 1.9 ml of PBS containing antibiotics (100
U/ml penicillin and 100 mg/ml streptomycin) to which were added 100 ml PBS containing the test
compound for a final volume of 1.5 ml. At the end of the incubation, aliquots of 0.1 ml were injected i.p.
into intact syngenic CBA mice of which survival time was recorded.
Brain metastases. The determination of the occurrence of leukemic brain involvement was performed
by means of a vivo-vivo bioassay. Briefly, whole brains of mice transplanted with TI_X5 lymphoma cells
one week before, were aseptically removed after killing of the animal by cervical dislocation. Brains
were subsequently transplanted s.c. in the flank of intact syngenic CBA mice by means of a sterile
syringe with a 19x21 needle. The survival time of the transplanted mice gave an indirect measure of the
amount of TLX5 lymphoma cells present in the transplanted brains (12,13).
Cytofluorimetric analys!s. Propidium iodide staining was performed according to the procedure
described by Krishan (14). Orange acridine staining was performed according to the methods of
Dar-zynkiewicz (15).
Statistical analysis. All data were subjected to statistical analysis by means of the computerized
Student-Newmann-Keuls test or the t-test for grouped data. Statistical differences were accepted at the
cut-off threshold of at least p<0.05.
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Animal studies. Animal studies were carried out according to the guidelines actually in force in Italy and
according to the Guide for the Care and Use of Laboratory Animals. DHHS Publ. No (NIH) 86-23.
Bethesda, Md N IH, 1985.
RESULTS
Effects on primary tumor and metastasis formation. The effects of the administration of 100 mg/kg/day
Na[trans-RuCl(DMSO)lm] on days 1,5,9,13 after i.m. implantation of 2x10 MCa mammary carcinoma
cells on day 0 in CBA mice immunesuppressed by 240 mg/kg Dacarbazine on day -2, are evaluated by
measuring the growth of primary tumor and of spontaneous lung metastases in two further groups of
CBA animals (untreated or treated with the same dose and treatment schedule of Na[trans-
RuCI(DMSO)Im]) [generation 1]) to which the treated tumor cells were transplanted following removal
on day 14. This experiment was continued for up to 8 transplant generations (Figure 1, Panels B and
C).
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Figure 1. Effects of in vivo treatment of MCa mammary carcinoma with Na[trans-RuCI4(DMSO)lm] for 8 transolant generations
on primary tumor growth and on lung metastasis formation. Groups of 5 CBA mice, implanted i.m. with 10 MCa mammary
carcinoma cells on day 0 and immunosuppressed with 240 mg/kg DTIC i.p. on day -2, were given Na[trans-RuCI4(DMSO)lm] (100
mg/kg/day on days 1,5,9,13). On day 14, primary tumors were removed, pooled and transplanted into two groups (A and B) of 8
intact CBA syngenic hosts each (transplant generation 1) and into a group of 5 CBA mice immunosuppressed as above (C).
Groups B and C were further treated with the same dose and treatment schedule of Na[trans-RuCI,t(DMSO)lm]; group C was
further processed as the initial treated group giving transplant generation 2 and so on. Pdmary tumor growth was measured on
day 14 and lung metastasis formation was evaluated on day 25 after tumor transplantation.
The analysis of data obtained from all 8 transplant generations shows no significant modification of
the response of primary tumor to Na[trans-RuCl(DMSO)lm], whereas lung metastasis formation was
markedly affected starting from generation 4 onwards. A detail of the curve of pdmary tumor growth and
of the reduction of spontaneous lung metastases is given in Figure 2, Panel B. The growth of MCa
mammary carcinoma in untreated mice is regular at all transplant generations and is not statistically
different of that of the intact untreated MCa mammary carcinoma, parental line in both intact and
immunosuppressed mice. An example of the curves of tumor growth is given in Figure 2, Panel A.
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Figure 2. Comparison of the growth of the primary tumor of MCa mammary carcinoma untreated or treated with Na[trans-
RuCl,(DMSO)lm].Groups of 5 CBA mice intact or immunosuppressed with DTIC, impldnted with 23(106 MCa mammary carcinoma
cells obtained from the primary tumor of immunosuppressed mice untreated or treated with Na[trans-RuCI4(DMSO)lm] (100
mg/kg/day on days 1,5,9,13) for 6 transplant generations (Panel A) or for 4 transplant generations (Panel B), were examined for
primary tumor growth.
Effects on MCa polyploidy. The measurement of MCa mammary carcinoma polyploidy was performed
24 hr after last drug administration in intact mice transplanted with MCa mammary carcinoma treated in
immunesuppressed hosts. Treatment by Na[trans-RuCl,(DMSO)lm] of the MCa mammary carcinoma in
intact hosts line of generations 1-8 does not significantly modify the proportion of 2n, 4n and 8n
population compared with untreated controls (Figure 3); the proportion of cells is equivalent to that of
the parental tumor line.
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Figure 3. Effects of in rive treatment of MCa mammary carcinoma with Na[trans-RuCI4(DMSO)lm for 8 transplant generations on
tumor cell ploidy. 3 mice of groups A and B of transplant generations of Figure were killed on day 14 and pdmary tumors
removed, pooled and processed for the preparation of a tumor cell suspension stained with propidium iodide and read with the
cytofluorimeter.
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Effects on DNA-RNA activity in MCa carcinoma cells. Data reported in Figure 4 show that treatment of
MCa mammary carcinoma by Na[trans-RuCI4(DMSO)lm] in immunesuppressed hosts causes a
progressive increase of DNA and only a minor effect on of RNA activity (Figure 4, Panel A). This effect
is maintained in intact hosts trasplanted with this tumor (Figure 4, Panel B) and a further treatment with
Na[trans-RuCl(DMSO)lm] of the same tumor line in intact hosts does not appreciably increase this
effect (Figure 4, Panel C).
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Figure 4. Effects of in vivo treatment of MCa mammary carcinoma with Na[trans-RuCl(DMSO)lm] for 8 transplant generations on
DNA and RNA content. 3 mice of groups A and B of transplant generations of Figure and of the group of mice
immunesuppressed with DTIC were killed on day 14 and primary tumors removed, pooled and processed for the preparation of a
tumor cell suspension stained with acridine orange and read with the cytofluorimeter.
Histological analysis. Sections of primary tumor of MCa mammary carcinoma obtained from DTIC
immunosuppressed mice and treated with Na[trans-RuCl(DMSO)lm] were stained with Hematoxylin-
Eosin and CajaI-Callego dyes. From the combined examination of the two stainings it appears that
tumor growth progressively invades muscular fibers which however maintain their histological integrity.
No modification of tumor cell shape, cell nucleus and staining was detected between untreated and
treated mice. Furtheremore, no apparent difference of infiltrating leucocytes is noted between untreated
or treated tumors or with increasing transplant generations.
Effects on TLX5 lymphoma. TLX5 lymphoma cells, treated in vitro with 10-M Na[trans-RuCl(DMSO)lm]
for up to 13 transplant generations, do not show any reduction of tumor take and growth in both intact
or immunosuppressed hosts (Figure 5, Panel A). Similarly, no significant modification of the capacity of
TLX5 lymphoma cells to metastasize to the brain was detected by means of a vivo-vivo bioassay of
whole brains harvested from the test animals and aseptically transplanted into syngenic CBA intact
mice (Figure 5, Panel B).
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Figure S. Effects of in vitro treatment of TLX5 lymphoma with Na[trans-RuCI4(DMSO)lm] for 13 transplant generations on the
survival time of mice in vivo transplanted with the treated tumor cells or with whole brains. Groups of 6 intact CBA mice or
immunosuppressed with DTIC on day -2, transplanted i.p. with 105 cells of TLX5 lymphoma previously challenged in vitro with 10-4
M Na[trans-RuCI4(DMSO)lm], were examined for survival time (Panel A). 3 mice per group were killed on day 7 and their whole
brains transplanted s.c. in intact hosts whose survival time is reported in Panel B.
DISCUSSION
The examination of the effects of Na[trans-RuCl(DMSO)lm] on the growth of Mca mammary
carcinoma showed a reproducible selective antimetastatic effect prevailing over the effect on the growth
of primary tumors. No evidence was given yet as to stress the mechanism by which Na[trans-
RuCI(DMSO)Im] blocks metastasis formation. Several possibilities may be put forward and one of
them is the possibility that Na[trans-RuCl(DMSO)lm] modifies tumor cells, at primary site, causing the
appearance of a tumor line with reduced metastasizing ability. A preliminary experiment seemed to
suggest such possibility, showing that the transplantation of tumor cells obtained by in vivo treated
mice into intact syngenic recipients gave rise to a normal growth of primary tumor but to a pronounced
reduction of lung metastasis formation.
Therefore the present study was focused at evaluating the effects of the treatment for several
transplant generations of the same tumor line on tumor growth and metastasis formation. TLX5
lyrnphoma, already shown to be a tumor line poorly responding to Na[trans-RuCl(DMSO)lm], was used
because it offers good possibilities to highlight the occurrence of a chemical xenogenization similar to
that described by the group of Fioretti (8,9). Despite 13 transplant generations in which TLX5
lymphoma cells were always exposed to 10M Na[trans-RuCl,(DMSO)lm] for hr no change of tumor
growth and capacity to colonise the brain was detected. These data support the hypotesis that
Na[trans-RuCl(DMSO)lm] does not induce new antigenicity to tumor cells and that lung metastasis
formation of solid tumors are probably reduced by a mechanism different from xenogenization. In fact,
data from a similar experiment performed with the solid MCa mammary carcinoma shows again that no
apparent modification of tumor growth and of metastasis formation occur following in vivo treatment of
tumor cells for up to 8 transplant generations. In the same model, however, it appears that the
formation of spontaneous lung metastases becomes markedly more susceptible to the antimetastatic
action of Na[trans-RuCl(DMSO)lm] after 4 transplant generations, as results by the examination of the
response of the xenogenised tumor line to a further treatment with Na[trans-RuCl(DMSO)lm] in intact
hosts. At the same time, it appears that the activity of DNA, but not that of RNA, in tumor cells markedly
increased with the progression of the transplant generations.
Taken together these observations stress the already reported lack of cytotoxicity of Na[trans-
RuCI(DMSO)Im] for tumor cells and suggest that the interaction of this compound with tumor cells
does not induce resistence to the antimetastastic effect. Conversely it seems that the selection of a cell
population with higher sensitivity to its antimetastastic action is unrelated to an appreciable modification
of tumor take and growth in the syngenic hosts.
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